Swiss pharmaceutical giant Novartis’ fourth quarter earnings miss expectations as the group prepares to overhaul its Alcon division.
Swiss pharmaceutical giant Novartis’ fourth quarter earnings miss expectations as the group prepares to overhaul its Alcon division.